| 8.04 0.13 (1.64%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.63 | 1-year : | 13.58 |
| Resists | First : | 9.96 | Second : | 11.63 |
| Pivot price | 8.82 |
|||
| Supports | First : | 7.25 | Second : | 5.59 |
| MAs | MA(5) : | 8.48 |
MA(20) : | 8.57  |
| MA(100) : | 5.79 |
MA(250) : | 5.11 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 20.1 |
D(3) : | 36.5 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 9.96 | Low : | 3.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XBIT ] has closed above bottom band by 21.3%. Bollinger Bands are 78.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.34 - 8.39 | 8.39 - 8.44 |
| Low: | 7.4 - 7.46 | 7.46 - 7.51 |
| Close: | 7.95 - 8.04 | 8.04 - 8.12 |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Thu, 18 Apr 2024
XBiotech (NASDAQ:XBIT) Share Price Passes Above 50 Day Moving Average of $7.19 - MarketBeat
Thu, 18 Apr 2024
XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $7.19 - Defense World
Sat, 30 Mar 2024
XBiotech (NASDAQ:XBIT) Share Price Crosses Above Fifty Day Moving Average of $6.09 - Defense World
Fri, 22 Mar 2024
XBiotech (NASDAQ:XBIT) Share Price Passes Above 50-Day Moving Average of $5.74 - MarketBeat
Mon, 18 Mar 2024
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023 - InvestorPlace
Fri, 08 Mar 2024
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 36 (%) |
| Held by Institutions | 11.4 (%) |
| Shares Short | 605 (K) |
| Shares Short P.Month | 537 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10 % |
| Return on Equity (ttm) | -10.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -9.93 |
| PEG Ratio | 0 |
| Price to Book value | 1.11 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|